Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Jul 17, 2020

SELL
$45.06 - $67.74 $10,183 - $15,309
-226 Closed
0 $0
Q2 2019

Aug 20, 2019

BUY
$52.76 - $82.19 $11,923 - $18,574
226 New
226 $18,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $740M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Salomon & Ludwin, LLC Portfolio

Follow Salomon & Ludwin, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Salomon & Ludwin, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Salomon & Ludwin, LLC with notifications on news.